This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Aiforia Technologies H2'25 Earnings Preview
Business earnings preview

Aiforia Technologies H2'25 Earnings Preview

Analysis based on 14 articles · First reported Feb 11, 2026 · Last updated Feb 27, 2026

Sentiment
20
Attention
2
Articles
14
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is likely to react positively to Aiforia Technologies' strong H2'25 sales growth and improved profitability outlook, especially the acceleration in clinical revenue. The reiterated BUY rating from NuWays AG further supports a positive sentiment for Aiforia Technologies' stock.

Biotechnology Medical devices Software
Event Summary

Aiforia Technologies is set to report its H2'25 results on March 6, with NuWays AG previewing a 47% year-over-year sales increase to €2.18m. Clinical revenue growth is expected to accelerate to 70% year-over-year, supported by increased adoption of pathology AI technology and strategic partnerships, notably with Siemens Healthineers. Research revenue is also projected to recover. Profitability is anticipated to improve, with H2'25 EBITDA expected at €-2.7m, driven by operational leverage and €2.5m in annual cost savings from November's workforce reductions. NuWays AG maintains a BUY rating with a €3.80 target price, citing Aiforia Technologies' strong cash position and long-term growth potential, particularly in the clinical segment for FY26-28.

Key Actions
90 Aiforia Technologies expected to report H2'25 results
70 NuWays AG reiterated BUY rating and EUR 3.8 target price Aiforia Technologies
70 Aiforia Technologies formed strategic partnership Siemens Healthineers
60 Aiforia Technologies concluded workforce reductions
Entities Involved
stock
Aiforia Technologies
Aiforia Technologies is expected to report strong H2'25 sales growth, particularly in its clinical segment, driven by increased adoption of pathology AI technology and strategic partnerships. The company's profitability is also projected to improve due to operational leverage and cost savings from workforce reductions.
Importance 100 Sentiment 20
stock
Siemens Healthineers
Siemens Healthineers is a strategic partner of Aiforia Technologies, and this partnership is expected to broaden Aiforia Technologies' commercial reach and help ramp up sales growth by embedding its AI solutions into large, established digital pathology networks.
Importance 40 Sentiment 0
priv
NuWays AG
NuWays AG is the research firm that published the H2'25 preview for Aiforia Technologies, reiterating a BUY rating and a target price of EUR 3.8.
Importance 30 Sentiment 0
per
Julius Neittamo
Julius Neittamo is the analyst from NuWays AG who authored the research report on Aiforia Technologies.
Importance 10 Sentiment 0
Relationships
NuWays AG related ↔ Aiforia Technologies
Siemens Healthineers related ↔ Aiforia Technologies
Julius Neittamo related ↔ NuWays AG
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.